IP Library Granted Patent US 11,180,472
Granted Patent B2
US 11,180,472 · App. 16/848,337 · Granted Nov 23, 2021

Antibacterial compounds

Inventors: Jérôme Émile Georges Guillemont (Andé, FR); Magali Madeleine Simone Motte (Louviers, FR); Pierre Jean-Marie Bernard Rabiosson (Rosieres, BE); Abdellah Tahri (Anderlecht, BE)
Assignee: Janssen Sciences Ireland UC
C07D401/12A61K31/404A61K31/429A61K31/437A61K31/438A61K31/444A61K31/4709A61K31/4745A61K31/496A61K31/498A61K31/4985A61K31/519A61K45/06A61P31/04A61P31/06C07D401/14C07D403/12C07D471/04C07D487/04C07D487/10C07D513/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,180,472
App. No.
16/848,337
Granted
Nov 23, 2021
Kind
B2
Abstract

The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.

Claims (19)

1. A process for preparing 6-chloro-2-ethyl-N-({4-[2-(trifluoromethanesulfonyl)-2-azaspiro[3.3]heptan-6-yl]phenyl}methyl)imidazo[1,2-a]pyridine-3-carboxamide, which comprises converting intermediate FF,

or a salt thereof, to 6-chloro-2-ethyl-N-({4-[2-(trifluoromethanesulfonyl)-2-azaspiro[3.3]heptan-6-yl]phenyl}methyl)imidazo[1,2-a]pyridine-3-carboxamide.

2. The process as claimed in claim 1 , wherein the intermediate FF is in the form of a HCl salt.

3. The process as claimed in claim 1 , wherein the converting is performed in the presence of Tf 2 O.

4. The process as claimed in claim 3 , wherein the intermediate FF is prepared by deprotection of intermediate FE,

5. The process as claimed in claim 4 , wherein the intermediate FE is prepared by reaction of intermediate FD,

with the following compound,

6. The process for the preparation of 6-chloro-2-ethyl-N-({4-[2-(trifluoromethanesulfonyl)-2-azaspiro[3.3]heptan-6-yl]phenyl}methyl)imidazo[1,2-a]pyridine-3-carboxamide, which comprises a process according to the following scheme:

7. A compound intermediate FF:

8. The process as claimed in claim 2 , wherein the converting is performed in the presence of Tf 2 O.

9. The process as claimed in claim 1 , wherein the intermediate FF is prepared by deprotection of intermediate FE,

10. The process as claimed in claim 2 , wherein the intermediate FF is prepared by deprotection of intermediate FE,

11. The process as claimed in claim 8 , wherein the intermediate FF is prepared by deprotection of intermediate FE,

12. The process as claimed in claim 9 , wherein the intermediate FE is prepared by reaction of intermediate FD,

with the following compound,

13. The process as claimed in claim 10 , wherein the intermediate FE is prepared by reaction of intermediate FD,

with the following compound,

14. A process as claimed in claim 11 , wherein the intermediate FE is prepared by reaction of intermediate FD,

with the following compound,

Assignments (1)
CHANGE OF NAME Recorded Nov 17, 2021
From: JANSSEN SCIENCES IRELAND UC
To: JANSSEN SCIENCES IRELAND UNLIMITED COMPANY
Reel/Frame 058173/0879 →
Priority Claims (3)
EP 15174936 · Jul 2, 2015 · regional
EP 16174713 · Jun 16, 2016 · regional
EP 16174718 · Jun 16, 2016 · regional
Continuity (3)
Continuation 16460334 · Jul 2, 2019
Division 15736375
Related Publication 20200239434A1 · Jul 30, 2020